The first human Lyme disease vaccine was 73% effective against the tick-borne illness, says Pfizer. They still plan to seek ...

Pfizer is working to get approval on a new vaccine that could protect people against Lyme disease.

Pfizer is working to get approval on a new vaccine that could protect people against Lyme disease. WBZ-TV's Mike Sullivan ...

The vaccine demonstrated a reduction in the rate of infections, but fell short of a key statistical requirement.

Earlier this week, pharmaceutical company Pfizer and its partner Valneva announced that an experimental Lyme disease vaccine ...

Every year, hundreds of thousands of Americans are diagnosed with Lyme disease, according to the Centers for Disease Control ...

Dr. Todd Ellerin of South Shore Health discusses the experimental Lyme disease vaccine that will go in front of the FDA.

Pfizer said its experimental Lyme disease vaccine was more than 70% efficacious in reducing confirmed cases of the tickborne ...

Drugmaker Pfizer and French vaccine company Valneva said their vaccine, called LB6V, worked more than 70% of the time in a clinical trial to prevent Lyme disease in people ages 5 and older. The ...

If approved by regulators, it could become the only Lyme disease vaccine available for people — although it would not be the first.

Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed ‌more than 70% efficacy in a ...

The companies said the vaccine was 73% effective in reducing the rate of Lyme disease 28 days after the fourth dose.